Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

4 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(33.3%)

Phase 3

4(33.3%)

N/A

3(25.0%)

Phase 1

1(8.3%)

12Total

Phase 2(4)

Phase 3(4)

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT07525427Phase 2Recruiting

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Role: collaborator

NCT05267613Phase 3Active Not Recruiting

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

Role: collaborator

NCT07712484Phase 2Not Yet Recruiting

A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM ) Treated With Olorofim Plus Baseline SOC or Placebo Plus Baseline SOC

Role: collaborator

NCT07517445Phase 2Recruiting

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

Role: collaborator

NCT05110261Phase 3Completed

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

Role: collaborator

NCT07430917Phase 2Not Yet Recruiting

Safety and Efficacy of J147 in Acute Ischemic Stroke

Role: collaborator

NCT05843916Phase 3Completed

Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease

Role: collaborator

NCT05904938Not ApplicableUnknown

Oral Administration of Actitan-F in Paediatric Diarrhoea